



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore- 452 015. Fax : 0731-2723017

Tel. : 0731 - 2723016, 4066516 Email : biofilchemicals@yahoo.com

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-4011700, 2420926, 2424003, 2423435 Fax : 4011740

CIN. L24233MP1985PLC002709

To,
The Secretary
Bombay stock Exchange Limited
P.J. Tower
Dalal street
Mumbai

Dated: 14th August, 2014

To,
The Secretary,
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Dear sirs,


Sub. : Un-Audited Financial results for the Quarter ended 30th June, 2014.

In compliance with Clause 41 of the Listing Agreement, we are submitting herewith the Un-Audited Financial results for the quarter ended on 30th June, 2014 duly approved by the board of the Directors of the Company in their meeting held on 14/08/2014.

This is for your information and record.

Thanking you,
Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Romil Shah
Director
(DIN No. 00326110)



Enc a/a



LIMITED REVIEW REPORT
FOR THE QUARTER ENDED ON 30TH JUNE 2014

We have reviewed the accompanying statement of unaudited financial results of **M/S. BIOFIL CHEMICALS & PHARMACEUTICALS LTD** (CIN L24233MP1985PLC002709) for the quarter ended 30th June 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.
Chartered Accountants
(Registration No: 002052C)

(S.N.Gadiya)
Proprietor
Membership No: 71229

Place: Indore
Date : 14/08/2014




Un-Audited Financial Results of Quarter Ended Jun. 2014
30-06-2014 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN NO. L24233MP1985PLC002709

Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE , 2014

Rs. In Lacs

PART I		(Rs. in Lakhs)			
	Particulars	3 months quarter ended 30/06/2014	3Months quarter ended 31/03/2014	Preceding 3 months quarter ended 30/06/2013	Audited for the year ended 31/03/2014
	(Refer Notes Below)	Reviwed	(Audited)	Reviwed	(Audited)
1	Income from operations				
	(a) Net sales/ income from operations (Net of Excise duty)	50.05	113.24	87.72	488.88
	(b) Other operating income	-	112.72	-	228.28
	Total income from operations (net)	50.05	225.97	87.72	717.17
2	Expenses				
	(a) Cost of materials consumed	13.28	13.88	51.72	153.78
	(b) Purchases of stock-in-trade	20.90	106.21	23.72	308.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2.14	(9.55)	(12.25)	18.17
	(d) Employee benefits expense	6.32	24.62	6.30	41.30
	(e) Depreciation and amortisation expense	5.56	6.46	5.25	22.23
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	7.68	10.85	5.71	99.14
	Total expenses	55.89	152.48	80.45	642.73
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(5.84)	73.49	7.27	74.44
4	Other income	14.63	2.83	1.05	5.98
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	8.79	76.32	8.32	80.42
6	Finance costs	3.75	4.11	3.75	15.36
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	5.04	72.21	4.57	65.06
8	Exceptional items		1.00		1.00
9	Profit / (Loss) from ordinary activities before tax (7 +8)	5.04	71.21	4.57	64.06
10	Tax expense		12.40		12.40
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	5.04	58.81	4.57	51.66
12	Minority interest *				
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	5.04	58.81	4.57	51.66
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10
15	Reserve excluding Revaluation Reserves				-1220.02
16.i	Earnings per share (before extraordinary items)				
	(of Rs. 10/- each) (not annualised):				
	(a) Basic	0.0031	0.0361	0.0028	0.0317
	(b) Diluted				



See accompanying note to the financial results

PART II

	Particulars	3 months quarter ended 30/06/2014	3Months quarter ended 31/03/2014	Preceding 3 months quarter ended 30/06/2013	Audited for the year ended 31/03/2014
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	- Number of shares	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **				
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
	b) Non - encumbered				
	- Number of shares	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82

	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil

Notes

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 14th August 2014
2. Figures have been regrouped wherever necessary including as per revised schedule VI
3. The Statuary auditors have carried out a limited review of the result for quarter ended 30th June 2014

Date : 14.08.2014

Place : Indore


ROMIL SHAH
 DIRECTOR
 (DIN NO. 00326110)



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results an Capital Employed for Quarter ended 30th June 2014
(Under Clause 41 Listing Agreement)

Rs. In lacs


S.No.	Segment Revenue	Quarter Ended			
		June 30 ,	March 31,	June 30 ,	31 March
		2014	2014	2013	2014
		Reviewed	Audited	Reviewed	Audited
1	Segment Revenue				
	Pharma Unit	27.23	201.69	16.46	545.97
	Chemicals Division	14.60	62.99	56.37	144.65
	Plastic Division	8.22	0.54	14.90	26.54
	Other	14.63	3.34	1.05	6.49
	Gross Turnover	64.68	268.56	88.80	723.66
2	Segment Results				
	Pharma Unit	15.26	83.75	(1.25)	158.29
	Chemicals Division	(3.07)	(78.94)	11.82	(72.58)
	Plastic Division	(3.40)	(29.94)	(2.25)	(7.52)
	Other	0.00	0.07	0.00	1.12
	Total Segment Profit Before Tax	8.79	(25.06)	8.32	79.31
	Interest Income	0.00	0.43	0.00	0.43
	Interest Expenses	3.75	3.82	3.75	15.07
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	5.04	(28.45)	4.57	64.67
	Provision for current tax	0.00	12.32	-	12.32
	Profit After Tax	5.04	(40.77)	4.57	51.35
3	Capital Employed				
	(Segment Assets- Segment Liabilities)				
	Pharma Unit	46.01	137.25	46.01	137.25
	Chemicals Division	732.09	689.52	732.09	689.52
	Plastic Division	(39.55)	(52.88)	(39.55)	(52.88)
	Other	(3.86)	-	(3.86)	-
	Total Capital Employed	734.69	773.90	734.69	773.90

DATE : 14-08-2014
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

ROMIL SHAH
DIRECTOR

(DIN NO. 00326110)



BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30-06-2014
CIN NO. L24233MP1985PLC002709

(In Rs.)

Standalone / Consolidated Statement of Assets and		As At	As at
Liabilities		(Current year end)	(Current year end)
	Particulars	30-06-2014	31-03-2014
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	(83604795)	(84108795)
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	79133205	78629205
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	28992658	28705158
	(b) Trade payables	35027896	36357692
	(c) Other current liabilities	-	-
	(d) Short-term provisions	637539	2294621
	Sub-total Current liabilities	64658093	67357471
	TOTAL - EQUITY AND LIABILITIES	143791298	145986676
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assests	91176634	91732634
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	91176634	91732634
2	Current assets		
	Current investments		
	Inventories	1864022	2735670
	Trade receivables	42599844	41041109
	Cash and cash equivalents	669194	1792975
	Short-term loans and advances	4979984	6153148
	Other current assets	2501620	2531139
	Sub-total - Current assets	52614664	54254042
	TOTAL - ASSETS	143791298	145986676

DATE : 14-08-2014

PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

ROMIL SHAH
DIRECTOR

(DIN NO. 00326110)

